All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. Use of point-of care devices in patients with oral anticoagulation : a Health Technology Assessment

    KCE Reports 117 (2009)

    https://kce.fgov.be/en/use-of-point-of-care-devices-in-patients-with-oral-anticoagulation-a-health-technology-assessment

  2. Use of pneumococcal vaccines in the elderly: an economic evaluation

    KCE Reports 274 (2016) Supplementary material pdf fileR274_Supplementary-file_Univariate-sensitivity-analyses (13.95 MB) pdf fileR274_Supplementary-file_Sensitivity-analyses_PPV23-price (1.1 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_Net-benefit-Box-plots (1.16 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_CEAFs-and-CE-planes (58.74 MB) The results are also available in a searchable spreadsheet-database format for all scenario and sensitivity analyses.

    https://kce.fgov.be/en/use-of-pneumococcal-vaccines-in-the-elderly-an-economic-evaluation

  3. Trastuzumab in Early Stage Breast Cancer

    KCE Reports 34 (2006) 30 June (2nd edition; 22 June 2006, 1st edition)

    https://kce.fgov.be/en/trastuzumab-in-early-stage-breast-cancer

  4. Transcatheter Aortic Valve Implantation (TAVI): a Health Technology Assessment Update

    KCE Reports 163 (2011)

    https://kce.fgov.be/en/transcatheter-aortic-valve-implantation-tavi-a-health-technology-assessment-update

  5. Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: Health Technology Assessment

    KCE Reports 108 (2009)

    https://kce.fgov.be/en/tiotropium-in-the-treatment-of-chronic-obstructive-pulmonary-disease-health-technology-assessment

  6. Threshold values for cost-effectiveness in health care

    KCE Reports 100 (2008)

    https://kce.fgov.be/en/threshold-values-for-cost-effectiveness-in-health-care
  7. Senior couple on contry bike

    The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making

    KCE Reports 324 (2019)  

    https://kce.fgov.be/en/the-use-of-statins-in-the-primary-prevention-of-cardiovascular-disease-an-online-tool-for-shared

  8. The role of biomarkers in ruling out cerebral lesions in mild cranial trauma

    KCE Reports 261 (2016)

    https://kce.fgov.be/en/the-role-of-biomarkers-in-ruling-out-cerebral-lesions-in-mild-cranial-trauma

  9. The non-invasive prenatal test (NIPT) for trisomy 21 – health economic aspects

    KCE Reports 222 (2014)

    https://kce.fgov.be/en/the-non-invasive-prenatal-test-nipt-for-trisomy-21-%E2%80%93-health-economic-aspects

  10. The Implantable Cardioverter Defibrillator: a Health Technology Assessment

    KCE Reports 58 (2007)

    https://kce.fgov.be/en/the-implantable-cardioverter-defibrillator-a-health-technology-assessment
  11. Senior couple on contry bike

    Statins for the primary prevention of cardiovascular events

    KCE Reports 306 (2019) A healthy lifestyle remains the most effective way of avoiding cardiovascular diseases and their consequences. Yet since 2002, the annual number of people who use cholesterol-lowering drugs from the statin family increased from 400,000 to 1,500,000. Currently, 25% of the population aged 40 and above take these drugs. Despite decreases in price due to the fact that all statins now exist in generic form, their total cost still stands at 160 million euros annually.

    https://kce.fgov.be/en/statins-for-the-primary-prevention-of-cardiovascular-events
  12. Defibrillator

    Static automated external defibrillators for opportunistic use by bystanders

    KCE Reports 294 (2017)

    https://kce.fgov.be/en/static-automated-external-defibrillators-for-opportunistic-use-by-bystanders

  13. Seasonal influenza vaccination: prioritizing children or other target groups? - Part II

    KCE Reports 204 (2013)

    https://kce.fgov.be/en/seasonal-influenza-vaccination-prioritizing-children-or-other-target-groups-part-ii

  14. Robot-assisted surgery: health technology assessment

    KCE Reports 104 (2009)

    https://kce.fgov.be/en/robot-assisted-surgery-health-technology-assessment
  15. 3D printing illustration

    Responsible use of high-risk medical devices: the example of 3D printed medical devices

    KCE Reports 297 (2018) 3D printing is generating increased interest in the medical sector, namely in orthopaedics and dentistry, but there is no evidence that 3D-printed implants are as effective or safe as “classical” products. Yet they can currently be used without restrictions by doctors, even when they are “at high risk” (that is, more often than not, implantable).

    https://kce.fgov.be/en/responsible-use-of-high-risk-medical-devices-the-example-of-3d-printed-medical-devices

  16. Remote monitoring for patients with implanted defibrillators. Technology evaluation and broader regulatory framework

    KCE Reports 136 (2010)

    https://kce.fgov.be/en/remote-monitoring-for-patients-with-implanted-defibrillators-technology-evaluation-and-broader
  17. Scaner with a nurse

    Proton beam therapy in adults

    KCE Reports 307 (2019) Proton therapy is a radiation therapy technique which allows large doses of radiation to be delivered to cancerous tumours without (excessively) “overflowing” to adjacent tissues. There has been much talk of this technique in recent years, since two projects by proton therapy centres are ongoing in Belgium, one in Louvain and the other in Charleroi.

    https://kce.fgov.be/en/proton-beam-therapy-in-adults
  18. R327_Nurse-showing-patient-donating

    Polyvalent immunoglobulins – Part 2: Use in Belgium

    KCE Reports 336 (2020)  

    https://kce.fgov.be/en/polyvalent-immunoglobulins-%E2%80%93-part-2-use-in-belgium
  19. R327_Nurse-showing-patient-donating

    Polyvalent immunoglobulins – Part 1: A rapid review

    KCE Reports 327 (2019)  

    https://kce.fgov.be/en/polyvalent-immunoglobulins-%E2%80%93-part-1-a-rapid-review

  20. Policies for Rare Diseases and Orphan Drugs

    KCE Reports 112 (2009)

    https://kce.fgov.be/en/policies-for-rare-diseases-and-orphan-drugs

Pages